Journey Medical announces a conference call to discuss the commercial launch of Emrosi, an FDA-approved rosacea treatment.
Quiver AI Summary
Journey Medical Corporation announced a conference call scheduled for February 5, 2025, to discuss the commercial launch plan for Emrosi™, an FDA-approved medication for treating inflammatory lesions of rosacea in adults. Emrosi, developed in collaboration with Dr. Reddy’s Laboratories, was approved in November 2024. Journey Medical's CEO, Claude Maraoui, expressed enthusiasm for Emrosi's launch, detailing plans for manufacturing and a dermatology-focused sales strategy to establish it as a new standard treatment for adult rosacea. The press release also provided important safety information regarding Emrosi, including potential adverse reactions and contraindications, and emphasized the prevalence of rosacea, which affects millions of people worldwide.
Potential Positives
- Announcement of the FDA approval of Emrosi™ for the treatment of inflammatory lesions of rosacea, expanding the company's product offerings.
- Management is hosting a conference call to discuss the commercial launch plan of Emrosi™, indicating proactive engagement with stakeholders.
- Emrosi™ aims to establish itself as a new oral standard of care for adult rosacea patients, which could significantly impact market positioning.
- The company's seasoned dermatology-focused sales force is preparing for the product launch, suggesting a well-structured marketing strategy for rollout.
Potential Negatives
- Potential safety concerns regarding Emrosi, including serious adverse reactions such as anaphylaxis and Stevens-Johnson syndrome, could affect its market acceptance and sales.
- The substantial doubt about the company's ability to continue as a going concern raises concerns over its financial stability and long-term viability.
- Reliance on a single product for revenue generation increases vulnerability to market fluctuations and competition, which could adversely impact financial results.
FAQ
What is Emrosi and what condition does it treat?
Emrosi™ is an FDA-approved medication for treating inflammatory lesions of rosacea in adults.
When is the conference call for Emrosi's launch update?
The conference call will take place on February 5, 2025, at 4:30 p.m. ET.
What are the common side effects of Emrosi?
The most common side effect is dyspepsia, reported in ≥1% of treated subjects.
How can I listen to the Emrosi conference call?
Dial 1-866-777-2509 (U.S.) or 1-412-317-5413 (international) about 10 minutes before the start.
What safety information should be considered before using Emrosi?
Patients should be aware of potential allergic reactions, liver injury, and effects on pregnancy and bone growth.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DERM Insider Trading Activity
$DERM insiders have traded $DERM stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DERM stock by insiders over the last 6 months:
- JOSEPH BENESCH (CFO) sold 9,324 shares for an estimated $51,002
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DERM Hedge Fund Activity
We have seen 15 institutional investors add shares of $DERM stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 148,322 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $838,019
- ACADIAN ASSET MANAGEMENT LLC removed 52,694 shares (-55.8%) from their portfolio in Q3 2024, for an estimated $297,721
- WALLEYE CAPITAL LLC removed 40,481 shares (-63.7%) from their portfolio in Q3 2024, for an estimated $228,717
- ENVESTNET ASSET MANAGEMENT INC removed 21,985 shares (-16.7%) from their portfolio in Q3 2024, for an estimated $124,215
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. added 19,500 shares (+6.6%) to their portfolio in Q3 2024, for an estimated $110,175
- VANGUARD GROUP INC added 14,923 shares (+4.8%) to their portfolio in Q3 2024, for an estimated $84,314
- TITLEIST ASSET MANAGEMENT, LLC added 14,250 shares (+inf%) to their portfolio in Q3 2024, for an estimated $80,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that its management team will host a conference call to provide an update on the commercial launch plan for Emrosi ™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November of 2024. Emrosi was developed in collaboration with Dr. Reddy’s Laboratories Ltd.
Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, said, “We are excited to provide an update on the upcoming launch of Emrosi, including progress on our pre-commercial activities, launch timing and our commercial plans. We are completing the manufacturing of Emrosi launch quantities for the U.S. market, and our seasoned dermatology-focused sales force is preparing for a successful roll out of the product. In line with the approved label, we intend to execute a launch strategy to drive Emrosi toward becoming a new oral standard of care for adult rosacea patients.”
Conference Call and Webcast Information
Journey Medical management will conduct a conference call and webcast to provide an update on the commercial launch plan for Emrosi on February 5, 2025, at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call. Participants can register for the conference here: https://dpregister.com/sreg/10196252/fe5c1eeee0 . Please note that registered participants will receive their dial-in number upon registration.
A live webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com , and will remain available for replay for approximately 30 days after the meeting.
Important Safety Information
Indication:
EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults.
Adverse Events:
The most common adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia.
Contraindications:
EMROSI should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines.
Warnings/Precautions:
Cases of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch
or call 1-800-FDA-1088.
For full prescribing information, please visit www.emrosi.com .
About Rosacea
Rosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to
The National Rosacea Society
,
it is estimated that rosacea affects over 16 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by
The National Rosacea Society
report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com
.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, Emrosi
TM
, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
[email protected]
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]